CN102675449A - 缺失型人角质细胞生长因子-ⅰ二硫键变构体及其用途 - Google Patents
缺失型人角质细胞生长因子-ⅰ二硫键变构体及其用途 Download PDFInfo
- Publication number
- CN102675449A CN102675449A CN2011100638146A CN201110063814A CN102675449A CN 102675449 A CN102675449 A CN 102675449A CN 2011100638146 A CN2011100638146 A CN 2011100638146A CN 201110063814 A CN201110063814 A CN 201110063814A CN 102675449 A CN102675449 A CN 102675449A
- Authority
- CN
- China
- Prior art keywords
- disulfide linkage
- hkgf
- growth factor
- natural
- deletion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000012010 growth Effects 0.000 title claims abstract description 30
- 238000012217 deletion Methods 0.000 title claims abstract description 18
- 230000037430 deletion Effects 0.000 title claims abstract description 18
- 210000002510 keratinocyte Anatomy 0.000 title claims abstract description 17
- 230000035772 mutation Effects 0.000 title abstract description 8
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 19
- 230000004761 fibrosis Effects 0.000 claims abstract description 19
- 230000031018 biological processes and functions Effects 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 13
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 12
- 230000002062 proliferating effect Effects 0.000 claims abstract description 12
- 238000005516 engineering process Methods 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 230000002792 vascular Effects 0.000 claims abstract description 8
- 238000004153 renaturation Methods 0.000 claims abstract description 7
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 114
- 230000003281 allosteric effect Effects 0.000 claims description 80
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 30
- 150000001413 amino acids Chemical class 0.000 claims description 21
- 235000001014 amino acid Nutrition 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 18
- 241000894006 Bacteria Species 0.000 claims description 16
- 230000037396 body weight Effects 0.000 claims description 15
- 230000010261 cell growth Effects 0.000 claims description 12
- 230000008859 change Effects 0.000 claims description 12
- 108010033040 Histones Proteins 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 10
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 8
- 210000004204 blood vessel Anatomy 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 7
- 206010020718 hyperplasia Diseases 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 210000003491 skin Anatomy 0.000 claims description 7
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 6
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 5
- 108020004511 Recombinant DNA Proteins 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 230000008034 disappearance Effects 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims description 3
- 238000013270 controlled release Methods 0.000 claims description 3
- 230000008556 epithelial cell proliferation Effects 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 230000009465 prokaryotic expression Effects 0.000 claims description 3
- 201000002793 renal fibrosis Diseases 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 206010025421 Macule Diseases 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 229920000832 Cutin Polymers 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 18
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 4
- 235000018417 cysteine Nutrition 0.000 abstract 4
- 229940121657 clinical drug Drugs 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 239000013558 reference substance Substances 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 14
- 241000700159 Rattus Species 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 238000001142 circular dichroism spectrum Methods 0.000 description 10
- 238000004043 dyeing Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000004087 cornea Anatomy 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 6
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 229960002591 hydroxyproline Drugs 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 210000003995 blood forming stem cell Anatomy 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 108010006654 Bleomycin Proteins 0.000 description 4
- 208000028006 Corneal injury Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102000003929 Transaminases Human genes 0.000 description 4
- 108090000340 Transaminases Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 229960001561 bleomycin Drugs 0.000 description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000003118 histopathologic effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003805 vibration mixing Methods 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical group C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 229960005382 phenolphthalein Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 108010046845 tryptones Proteins 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- -1 DTT) Chemical compound 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 description 1
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 1
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- AHEBIAHEZWQVHB-QTKMDUPCSA-N His-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O AHEBIAHEZWQVHB-QTKMDUPCSA-N 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 101100498071 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-17 gene Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940012466 egg shell membrane Drugs 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 208000037888 epithelial cell injury Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 206010023683 lagophthalmos Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000032646 lung growth Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000002577 ophthalmoscopy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (17)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110063814.6A CN102675449B (zh) | 2011-03-17 | 2011-03-17 | 缺失型人角质细胞生长因子-ⅰ二硫键变构体及其用途 |
PCT/CN2012/000345 WO2012122859A1 (zh) | 2011-03-17 | 2012-03-19 | 人角质细胞生长因子-ⅰ二硫键变构体及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110063814.6A CN102675449B (zh) | 2011-03-17 | 2011-03-17 | 缺失型人角质细胞生长因子-ⅰ二硫键变构体及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102675449A true CN102675449A (zh) | 2012-09-19 |
CN102675449B CN102675449B (zh) | 2016-06-08 |
Family
ID=46808050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110063814.6A Active CN102675449B (zh) | 2011-03-17 | 2011-03-17 | 缺失型人角质细胞生长因子-ⅰ二硫键变构体及其用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102675449B (zh) |
WO (1) | WO2012122859A1 (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1310944C (zh) * | 2003-01-13 | 2007-04-18 | 重庆富进生物医药有限公司 | 新型人角质细胞生长因子突变体 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT785949E (pt) * | 1994-10-13 | 2003-09-30 | Amgen Inc | Metodo para purificar factores de crescimento de queratinocitos |
PL1827483T3 (pl) * | 2004-12-15 | 2014-12-31 | Swedish Orphan Biovitrum Ab Publ | Formulacje terapeutyczne czynnika wzrostu keratynocytów |
-
2011
- 2011-03-17 CN CN201110063814.6A patent/CN102675449B/zh active Active
-
2012
- 2012-03-19 WO PCT/CN2012/000345 patent/WO2012122859A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1310944C (zh) * | 2003-01-13 | 2007-04-18 | 重庆富进生物医药有限公司 | 新型人角质细胞生长因子突变体 |
Non-Patent Citations (2)
Title |
---|
ERIC HSU等: "Enhanced stability of recombinant keratinocyte growth factor by mutagenesis", 《PROTEIN ENGINEERING, DESIGN & SELECTION》 * |
张增涛等: "重组人角质细胞生长因子I型缺失突变体二硫键配对与生物活性", 《重庆理工大学学报(自然科学)》 * |
Also Published As
Publication number | Publication date |
---|---|
CN102675449B (zh) | 2016-06-08 |
WO2012122859A1 (zh) | 2012-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7622445B2 (en) | Muteins of fibroblast growth factor 21 | |
US7582607B2 (en) | Muteins of fibroblast growth factor 21 | |
US7655627B2 (en) | Muteins of fibroblast growth factor 21 | |
US7816321B2 (en) | Thymosin β4 derivatives and use thereof | |
JP5701375B2 (ja) | 血管新生促進用ペプチド及びその使用 | |
CN116535486A (zh) | 一种角蛋白yk93-1、制法和其药物组合物与用途 | |
CN1367791A (zh) | 一种新的血管发生抑制剂 | |
US20210393501A1 (en) | Preparation method and application of recombinant mutant collagenase | |
CN102884073B (zh) | 用于促进血管生成的肽及其用途 | |
CN102675449A (zh) | 缺失型人角质细胞生长因子-ⅰ二硫键变构体及其用途 | |
CN109836487B (zh) | 一种人成纤维细胞生长因子18及其可溶性重组表达方法、制备方法、制剂和应用 | |
CN101921820B (zh) | 具有活性重组肿瘤特异性凋亡因子的制备方法及其制品的应用 | |
CN110183529B (zh) | 一种缺失型人角质细胞生长因子-1的重组制备方法 | |
CN1232532C (zh) | 成纤维细胞生长因子-2结构类似物,其生产方法及应用 | |
CN113214375B (zh) | 一种抗肿瘤僵蚕溶茧酶抑制剂及其纯化方法和应用 | |
KR102653532B1 (ko) | 수퍼옥시드 디스뮤타제 및 이의 건성안의 예방 또는 치료용 용도 | |
US20220088139A1 (en) | Nerve growth factor mutant | |
CN117737012A (zh) | 一种具有抗炎活性的类弹性融合蛋白TRX1-ELPs及其制备方法和应用 | |
CN110016082A (zh) | MIP3α-FGFR1-PD1/Fc融合蛋白及其核酸分子和应用 | |
CN104177501A (zh) | 蝎镇痛抗肿瘤缬精甘肽融合体及其获得方法 | |
CN101575372A (zh) | 一种人角质细胞生长因子-1结构类似物及其制备方法和应用 | |
CN1500809A (zh) | 成纤维细胞生长因子-2结构类似物,其生产方法及应用 | |
KR20130032787A (ko) | 심혈관 질환 예방 및 치료용 펩타이드 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170411 Address after: 400332 Chongqing city Shapingba Xiyong three road Technology Innovation Productivity Promotion Center 8 floor Patentee after: CHONGQING PAIJIN BIOTECHNOLOGY CO., LTD. Address before: 400041 Jiulongpo District of Chongqing Science Park 4 Street No. 70 6 floor Patentee before: Fujin Bio-Medicine Co., Ltd., Chongqing |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: No. 106 Fenghe Road, Beibei District, Chongqing Patentee after: CHONGQING PAIJIN BIOTECHNOLOGY CO., LTD. Address before: 400332 8th Floor, Innovative Productivity Promotion Center, Xiyong Science and Technology Third Road, Shapingba District, Chongqing Patentee before: CHONGQING PAIJIN BIOTECHNOLOGY CO., LTD. |